Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...

SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.

As mask mandates are lifted, and mitigation measures are increasingly dropped across the nation, a stark reality continues to hinder the nation's return to a pre-pandemic sense of normality. Hundreds ...

Although still indicated for many adults, Pfizer’s antiviral COVID-19 treatment has been shown to be less effective in recent studies than first believed. COVID-19 is rising in prevalence in many ...

Paxlovid, the five-day antiviral treatment for covid, may not reduce the risk of covid-related hospitalizations and all-cause deaths in vaccinated older adults, a new study suggests. Paxlovid - Pfizer ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

Johnson & Johnson’s pharmaceutical arm, Janssen, has shared early preclinical findings on its new antiviral drug, JNJ-9676, which shows promise in combating COVID-19 and other serious coronaviruses.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Antiviral therapy reduced incidence of long COVID-19 ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 clinical ...